Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Neuralstem To Present At Barclays Global Healthcare Conference 2015 | ||
By: PR Newswire Association LLC. - 04 Mar 2015 | Back to overview list |
|
GERMANTOWN, Md., March 4, 2015 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that Richard Garr, President and CEO, will present at the Barclays Global Healthcare Conference 2015 on Thursday, March 12, at 2:35 p.m. EDT in Miami. An audio webcast of the presentation will be broadcast simultaneously through the Investor Center home page of Neuralstem's website: investor.neuralstem.com. An archive of the presentation will also be available for 30 days. About Neuralstem Neuralstem is a dual platform regenerative medicine company. The company's technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem's small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company's lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem's first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic stroke. For more information, please visit www.neuralstem.com or connect with us on Twitter, Facebook and LinkedIn Cautionary Statement Regarding Forward Looking Information: Logo - http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO SOURCE Neuralstem, Inc. |
||
|
||
Copyright 2015 PR Newswire Association LLC. | Back to overview list |